Tag: herg screening industry trends

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Estimated Industry Valuation for the HERG Screening Sector?

In recent times, rapid expansion has been witnessed in the HERG screening market size. Its growth is projected to escalate from a robust $1.62 billion in 2024 to a whopping $1.84 billion in 2025, with a compound annual growth rate (CAGR) of 13.7%. The exponential growth during the historic period is linked to factors such as an upsurge in drug development activities, stringent regulatory protocols, heightened awareness regarding cardiac health, and a surge in the occurrence of cardiac disorders.

In the coming years, a swift expansion is anticipated in the HERG screening market, which is projected to reach “ $2.88 billion by 2029, with a compound annual growth rate (CAGR) of 11.9%.” Factors contributing to this growth during the projected period include the development of personalized medicine, the trend of outsourcing drug development initiatives, the growth of emerging markets and research, as well as emphasis on non-cardiac safety evaluation. Key trends predicted to impact this period are improvements in in vitro models, the merging of genomic and proteomic data, advancements in computational methodologies, a heightened focus on pediatric drug safety, and cooperative efforts for data sharing and standardization.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=14392&type=smp

What Forces Are Driving The Growth Of The HERG Screening Market?

The increase in heart disorder patients is set to push forward the expansion of the HERG screening market. Heart disorders, also recognized as cardiovascular diseases, are a variety of conditions that can harm the heart and blood vessels, compromising the heart’s capacity to function correctly and potentially leading to severe health issues. Factors such as unhealthy lifestyles, an aging population, genetic predisposition, diabetes, and metabolic syndrome can give rise to these disorders. HERG screening enables the discovery of potential drug prospects, prevention of cardiac incidents that could cause fatal cardiac arrhythmias, especially torsade de pointes (TdP), and enhancement of patient results. For example, a May 2023 report by the US-based Centers for Disease Control and Prevention revealed that 1 in 20 adults aged 20 and above were afflicted with cardiovascular diseases, with 695,000 persons living with these diseases and 375,476 persons dying from them. Moreover, a report from the UK-based Office for National Statistics published in March 2022 stated that 20,061 individuals died from heart attacks, indicating an increase from the previous year. As such, the surge in heart disorder patients is contributing to the escalation of the HERG screening market.

The herg screening market covered in this report is segmented –

1) By Type: Gene KCNH2, Mutant KCNH2

2) By Ion Channel: Voltage-Gated, Ligand Gated

3) By Applications: Antiarrhythmic, Antipsychotic, Antibiotics, Other Applications

Subsegments:

1) By Gene KCNH2: Wild-Type KCNH2, Recombinant KCNH2

2) By Mutant KCNH2: Mutations: Missense Mutations, Nonsense Mutations, Frameshift Mutations

How Are Key Trends Driving Expansion In The HERG Screening Industry?

Leading organisations in the HERG screening market are focusing on developing novel advanced solutions like GLP-certified HERG screening services to improve cardiac safety evaluations in drug development procedures. These services involve good laboratory practice-certified screening of the human ether-à-go-go related gene (hERG) using the standard whole-cell patch-clamp method. This ensures that the service complies with necessary standards such as ICH S7A and ICH S7B, which are vital for safety pharmacology research during drug creation. In August 2023, Metrion Biosciences Ltd., a pharmaceutical firm based in the UK, debuted its GLP-certified hERG screening service. The intention is to boost Metrion’s assistance for the evolution of small-molecule therapeutics and augment their current cardiac safety services. Moreover, this service uses the whole-cell patch-clamp methodology to examine possible cardiac risks before beginning Phase 1 of human clinical trials. It offers guidance on regulations for safety pharmacology studies in drug creation and presents customers with high-grade biology utilities for ion channel targets.

Which Companies Currently Dominate The Competitive Landscape In The HERG Screening Industry?

Major companies operating in the HERG screening market are Eurofins-Cerep SA., Aviva Biosciences Inc., AstraZeneca Public Limited Company, Merck KGaA, Charles River Laboratories Inc., Abcam Public Limited Company, Molecular Devices LLC, Caliper Life Sciences Inc., Crprotex Limited, ChanTest Corporation, Creative bioarray Inc., Cellular Dynamics International Inc., Nanion Technologies, Essen Bioscience, ABR-Affinity BioReagents Inc., ACEA Biosciences Inc., Metrion biosciences Inc., Aurora Biomed Inc., Aureus Sciences, RedShift BioAnalytics, B’SYS GmbH, Cambridge Bioscience Ltd., Sophion Bioscience Inc., Fluxion Biosciences Inc., ChemAxon Ltd.

https://www.thebusinessresearchcompany.com/report/herg-screening-global-market-report

Which Geographic Regions Are Driving Demand In The HERG Screening Market?

North America was the largest region in the HERG screening market in 2024. Asia-Pacific is expected to be the fastest growing region in the forecast period. The regions covered in the HERG screening market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=14392&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Current and Projected Market Size of the HERG Screening Market Through 2034?

The market size of HERG screening has experienced significant expansion in recent years. The market forecast suggests an increase from $1.62 billion in 2024 to $1.84 billion in 2025, at a compound annual growth rate (CAGR) of 13.7%. The substantial growth during the historic period can be credited to the escalation in drug development processes, adherence to regulatory norms, enhanced awareness concerning cardiac safety, and the increasing frequency of cardiac disorders.

In the coming years, the HERG screening market is projected to experience swift expansion. It’s anticipated to surge to $2.88 billion by 2029, with a compound annual growth rate (CAGR) of 11.9%. The expected growth during the forecast period is linked to the rise of personalized medicine, the escalation of outsourced drug development operations, the emergence of new markets and research, and an emphasis on non-cardiac safety evaluations. The forecasted period will also witness significant trends such as the evolution of in vitro models, the unification of genomic and proteomic data, advancements in computational methods, a focus on the safety of pediatric drugs, and partnerships for data sharing and standardization.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=14392&type=smp

What Are the Core Market Drivers Propelling Growth in the HERG Screening Industry?

The increase in heart disease patients is anticipated to boost the expansion of the HERG screening market. Heart diseases, also recognized as cardiovascular disorders, encompass a myriad of conditions that impact the heart and blood vessels, potentially leading to severe health issues. Factors such as unhealthy lifestyles, aging, genetic predispositions, diabetes, and metabolic syndrome contribute to these disorders. HERG screening is a critical tool for recognizing possible drug candidates, preventing harmful cardiac incidents which could trigger fatal cardiac arrhythmias, particularly torsade de pointes (TdP), and bettering patient outcomes. For example, a Centers for Disease Control and Prevention report from May 2023 showed that 1 in 20 U.S. adults over the age of 20 had cardiovascular diseases, with 695,000 suffering and 375,476 people dying from these conditions. Moreover, a March 2022 Office for National Statistics report stated that the death toll from heart attacks in the UK increased from the previous year to 20,061. Consequently, the escalating number of heart disease patients is fueling the HERG screening market’s growth.

How Is the HERG Screening Market Segmented?

The herg screening market covered in this report is segmented –

1) By Type: Gene KCNH2, Mutant KCNH2

2) By Ion Channel: Voltage-Gated, Ligand Gated

3) By Applications: Antiarrhythmic, Antipsychotic, Antibiotics, Other Applications

Subsegments:

1) By Gene KCNH2: Wild-Type KCNH2, Recombinant KCNH2

2) By Mutant KCNH2: Mutations: Missense Mutations, Nonsense Mutations, Frameshift Mutations

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=14392&type=smp

Which Regions Are Driving the Next Phase of the HERG Screening Market Growth?

North America was the largest region in the HERG screening market in 2024. Asia-Pacific is expected to be the fastest growing region in the forecast period. The regions covered in the HERG screening market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Key Market Trends and Innovations Are Shaping the Future of the HERG Screening Industry?

Leading firms involved in the HERG screening market are shifting their focus towards new cutting-edge advanced solutions such as GLP-certified HERG screening services to improve cardiac safety evaluations during drug development procedures. This service pertains to good laboratory practice-certified screening of the human ether-à-go-go related gene (hERG) using the traditional whole-cell patch-clamp method. It guarantees that the screening adheres to regulatory guidelines like ICH S7A and ICH S7B, which are crucial for safety pharmacology studies in drug development. For example, in August 2023, Metrion Biosciences Ltd., a pharmaceutical firm based in the UK, introduced the good laboratory practice (GLP) certified hERG screening service. This service’s main intent is to expand Metrion’s assistance for small-molecule therapeutic development and to supplement the company’s existing cardiac safety service range. Furthermore, this service employs the traditional whole-cell patch-clamp technique to evaluate potential cardiac liabilities prior to initiating Phase 1 clinical trials in humans. It also provides regulatory guidance for safety pharmacology studies in drug development and provides clients with top-notch biology services for ion channel targets.

View the full report here:

https://www.thebusinessresearchcompany.com/report/herg-screening-global-market-report

How Is the HERG Screening Market Defined and What Are Its Core Parameters?

Human Ether-à-go-go-related gene (HERG) screening refers to the process of assessing the potential cardiotoxicity of a drug or compound. HERG screening is an important component of preclinical safety assessment in drug discovery and development, ensuring the safety and efficacy of novel therapeutic agents.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=14392

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!

What Factors Are Propelling the Market Growth of theHERG Screening Market from 2025 to 2034?

The growth of the HERG screening market is anticipated to be fueled by the increasing number of individuals suffering from heart disorders. Heart disorders, alternatively known as cardiovascular diseases, encompass an array of conditions affecting the heart and blood vessels. These conditions can interfere with the heart’s normal functioning, leading to potentially severe health issues. Unhealthy lifestyles, aging, genetic predisposition, diabetes, and metabolic syndrome are primary contributors to these disorders. HERG screening plays a significant role in identifying promising drug candidates, averting cardiac events that could provoke fatal cardiac arrhythmias, notably torsade de pointes (TdP), and enhancing patient health outcomes. For instance, a report released by the Centers for Disease Control and Prevention, a US-based national public health agency, in May 2023 stated that 1 in 20 adults over 20 years have cardiovascular diseases. The report further noted that 695,000 individuals had cardiovascular diseases, with 375,476 of them succumbing to these diseases. Additionally, a report from the Office for National Statistics, a UK government department, in March 2022 pointed out that 20,061 people died from heart attacks, marking an increase from the previous year. Hence, the escalating numbers of heart disorder patients are stimulating the expansion of the HERG screening market.

Get Your Free Sample Report Now – Explore Exclusive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=14392&type=smp

#What Growth Opportunities Will Drive the HERG Screening Market’s CAGR Through 2034?

In recent times, the HERG screening market experienced a significant expansion. The market value, projected to increase from $1.62 billion in 2024 to $1.84 billion in 2025, is expected to grow at a compound annual growth rate (CAGR) of 13.9%. The historic growth trend is chiefly due to the rise in drug development efforts, changing governmental regulations, a growing focus on cardiac health safety, and a spike in heart-related ailments.

Expectations are high for the HERG screening market as it is forecasted to experience swift growth in the coming years. The projected growth could see the market reach $2.9 billion by 2029, with a compound annual growth rate (CAGR) of 12.0%. This growth in the forecast period is anticipated to be fuelled by the growth of personalized medicine, the rise in drug development outsourcing activities, and the expansion of emerging markets and research. The emphasis on non-cardiac safety assessments is another growth driver. Notable trends for the forecast period are the progression of in vitro models, the synergy of genomic and proteomic data, advancements in computational strategies, a focus on the safety of pediatric medicines, and collaborative measures for data sharing and standardization.

You can Directly Purchase the Report Here:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=14392

How Are Market Trends and Innovations Revolutionizing theHERG Screening Industry in Recent Times?

Leading firms in the HERG screening market are focusing on cutting-edge solutions, including GLP-certified HERG screening services, to improve cardiac safety evaluations during drug creation procedures. This service involves good laboratory practice-certified screening of the human ether-à-go-go related gene (hERG) utilizing the traditional whole-cell patch-clamp method. It guarantees that the screening adheres to regulatory standards such as ICH S7A and ICH S7B, which are crucial for safety pharmacology research in drug development. For example, Metrion Biosciences Ltd., a pharmaceutical company based in the UK, unveiled the good laboratory practice (GLP)-certified hERG screening service in August 2023. The purpose of this service is to strengthen Metrion’s contribution to small-molecule therapeutic creation and enhance the company’s existing cardiac safety service offerings. Besides, this service uses the traditional whole-cell patch-clamp method to identify potential cardiac risks before beginning Phase 1 clinical trials in humans. It also provides regulatory advice for safety pharmacology research in drug development and delivers customers top-quality biology services for ion channel objectives.

Which Key Market Players Are Shaping the Future and Growth of theHERG Screening Market?

Major companies operating in the HERG screening market are Eurofins-Cerep SA., Aviva Biosciences Inc., AstraZeneca Public Limited Company, Merck KGaA, Charles River Laboratories Inc., Abcam Public Limited Company, Molecular Devices LLC, Caliper Life Sciences Inc., Crprotex Limited, ChanTest Corporation, Creative bioarray Inc., Cellular Dynamics International Inc., Nanion Technologies, Essen Bioscience, ABR-Affinity BioReagents Inc., ACEA Biosciences Inc., Metrion biosciences Inc., Aurora Biomed Inc., Aureus Sciences, RedShift BioAnalytics, B’SYS GmbH, Cambridge Bioscience Ltd., Sophion Bioscience Inc., Fluxion Biosciences Inc., ChemAxon Ltd.

Order Your Report Now For A Swift Delivery:

https://www.thebusinessresearchcompany.com/report/herg-screening-global-market-report

What Are the Core Segments of the HERG Screening Market, and How Do They Contribute to Growth?

The HERG screening market covered in this report is segmented –

1) By Type: Gene KCNH2, Mutant KCNH2

2) By Ion Channel: Voltage-Gated, Ligand Gated

3) By Applications: Antiarrhythmic, Antipsychotic, Antibiotics, Other Applications

Subsegmeents:

1) By Gene KCNH2: Wild-Type KCNH2, Recombinant KCNH2

2) By Mutant KCNH2: Mutations: Missense Mutations, Nonsense Mutations, Frameshift Mutations

Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!

https://www.thebusinessresearchcompany.com/customise?id=14392&type=smp

What Regions Are Dominating the HERG Screening Market Growth?

North America was the largest region in the HERG screening market in 2024. Asia-Pacific is expected to be the fastest growing region in the forecast period. The regions covered in the HERG screening market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Reports Similar to the Global HERG Screening Market 2025, By The Business Research Company:

Cellular Health Screening Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/cellular-health-screening-global-market-report

Crushing, Screening, And Mineral Processing Equipment Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/crushing-screening-and-mineral-processing-equipment-global-market-report

Blood Screening Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/blood-screening-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

How has the HERG Screening market grown over the years?

In recent times, the HERG screening market has seen substantial growth. The market, which is predicted to rise from $1.62 billion in 2024 to $1.84 billion in 2025, will witness a compound annual growth rate (CAGR) of 13.9%. The previous growth seen can be credited to the heightened drug development activities, enforcement of regulatory guidelines, a surge in cardiac safety awareness, and an increase in the number of cardiac disorders.

What Is the forecasted market size and growth rate for the herg screening market?

The market size for HERG screening is projected to experience substantial expansion in the ensuing years, with expectations of reaching $2.9 billion in 2029 at a compound annual growth rate (CAGR) of 12.0%. The escalation throughout the forecast period can be accredited to the development of personalized medicine, the rise in outsourcing of drug development procedures, the emergence of new markets and research, and emphasis on non-cardiac safety evaluations. Principal trends during the forecast period encompass advanced in vitro models, the incorporation of genomic and proteomic data, advancements in computational methods, focusing on the safety of pediatric drugs, and alliances for data sharing and standardization.

Get your herg screening market report here!

https://www.thebusinessresearchcompany.com/report/herg-screening-global-market-report

What are the major factors driving growth in the herg screening market?

The burgeoning number of individuals suffering from heart conditions is anticipated to drive the expansion of the HERG screening market. Heart diseases, also referred to as cardiovascular disorders, encompass a variety of ailments that impact the heart and blood vessels. This can interfere with the heart’s optimal functioning and could result in severe health issues. Factors that contribute to these disorders include unhealthy lifestyles, an aging population, genetic predispositions, diabetes, and metabolic syndrome. HERG screening serves to detect potential drug candidates and prevent serious cardiac incidents that might trigger fatal cardiac arrhythmias, specifically torsade de pointes (TdP), thereby enhancing patient outcomes. For example, a report released by the US-based Centers for Disease Control and Prevention in May 2023 revealed that 1 out of 20 adults over the age of 20 suffer from cardiovascular disorders, accounting for 695,000 individuals, with 375,476 fatalities due to these diseases. Moreover, in March 2022, a report from the UK-based Office for National Statistics revealed that 20,061 individuals succumbed to heart attacks, showing an upward trend from the previous year. As such, the growing prevalence of patients with heart disorders is a significant factor in the escalating growth of the HERG screening market.

What key areas define the segmentation of the global herg screening Market?

The HERG screening market covered in this report is segmented –

1) By Type: Gene KCNH2, Mutant KCNH2

2) By Ion Channel: Voltage-Gated, Ligand Gated

3) By Applications: Antiarrhythmic, Antipsychotic, Antibiotics, Other Applications

Subsegmeents:

1) By Gene KCNH2: Wild-Type KCNH2, Recombinant KCNH2

2) By Mutant KCNH2: Mutations: Missense Mutations, Nonsense Mutations, Frameshift Mutations

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=14392&type=smp

What are the top market players propelling the growth of the herg screening industry?

Major companies operating in the HERG screening market are Eurofins-Cerep SA., Aviva Biosciences Inc., AstraZeneca Public Limited Company, Merck KGaA, Charles River Laboratories Inc., Abcam Public Limited Company, Molecular Devices LLC, Caliper Life Sciences Inc., Crprotex Limited, ChanTest Corporation, Creative bioarray Inc., Cellular Dynamics International Inc., Nanion Technologies, Essen Bioscience, ABR-Affinity BioReagents Inc., ACEA Biosciences Inc., Metrion biosciences Inc., Aurora Biomed Inc., Aureus Sciences, RedShift BioAnalytics, B’SYS GmbH, Cambridge Bioscience Ltd., Sophion Bioscience Inc., Fluxion Biosciences Inc., ChemAxon Ltd.

What are the key trends shaping the future of the herg screening market?

Leading firms in the HERG screening market are focusing on pioneering novel, sophisticated solutions like GLP-certified HERG screening services to improve cardiac safety evaluations during drug development phases. This involves the utilisation of the standard whole-cell patch-clamp process for good laboratory practice-certified screening of the human ether-à-go-go related gene (hERG), ensuring adherence to regulatory standards like ICH S7A and ICH S7B – vital for safety pharmacology studies within drug creation. As an illustration, in August 2023, the UK pharmaceutical organization, Metrion Biosciences Ltd., unveiled the GLP-certified hERG screening service. This service is designed to boost Metrion’s contribution to small-molecule therapeutic creation and augment the firm’s existing cardiac safety service range. Moreover, this service employs the standard whole-cell patch-clamp method to anticipate possible cardiac risks prior to the initiation of Phase 1 clinical trials on human subjects, provides regulatory advice for safety pharmacology studies during drug development, and presents clients with superior-quality biology services concerning ion channel targets.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=14392

What regions are dominating the herg screening market growth?

North America was the largest region in the HERG screening market in 2024. Asia-Pacific is expected to be the fastest growing region in the forecast period. The regions covered in the HERG screening market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Similar Reports By The Business Research Company:

Cellular Health Screening Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/cellular-health-screening-global-market-report

Crushing, Screening, And Mineral Processing Equipment Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/crushing-screening-and-mineral-processing-equipment-global-market-report

Blood Screening Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/blood-screening-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

What is the Expected Growth Rate of the HERG Screening Market Based on Industry Projections?

Recent years have seen a quick expansion in the size of the HERG screening market. Projected to rise from $1.62 billion in 2024 to $1.84 billion in 2025, this market demonstrates a compound annual growth rate (CAGR) of 13.9%. The growth observed during the historic period is largely due to the rise in pharmaceutical advancements, regulatory standards, increased consciousness concerning heart health, and a growing occurrence of heart-related ailments.

Over the next few years, a swift expansion is anticipated for the HERG screening market, predicted to reach a worth of $2.9 billion by 2029, coming to represent a compound annual growth rate (CAGR) of 12.0%. The projected growth in this period can largely be linked to the increasing embrace of personalized medicine, a surge in drug development activities being outsourced, the rise of emerging research markets, as well as a heightened emphasis on non-cardiac safety evaluations. Key trends in this forecast period comprise improvements in in vitro models, concerted efforts in combining genomic and proteomic data, progress in computational methodologies, a focus on the safety of pediatric drugs, and partnerships encouraging the standardization and sharing of data.

What Are the Primary Drivers Supporting the Growth of the herg screening Market?

The HERG screening market’s exponential growth is largely attributed to the increasing number of patients suffering from heart disorders. These disorders, also commonly referred to as cardiovascular diseases, encompass an array of conditions impacting the heart and blood vessels. Such conditions contribute to impaired heart functioning and pose serious health risks. Risk factors leading to these disorders involve unhealthy lifestyle choices, an aging population, genetic predispositions, diabetes, and metabolic syndrome. By employing HERG screening, potential drug candidates can be identified to prevent severe cardiac occurrences that could result in fatal cardiac arrhythmias, particularly torsade de pointes (TdP), thereby enhancing the patient’s health prognosis. For example, as per a May 2023 report compiled by the Centers for Disease Control and Prevention, a public health entity based in the US, cardiovascular diseases affected 1 in 20 adults aged 20 and over, with about 695,000 people grappling with these diseases, leading to 375,476 fatalities. Also, a report furnished by the Office for National Statistics, a governmental entity based in the UK, showed that heart attacks claimed the lives of 20,061 individuals in March 2022, marking an annual increase. Consequently, the growth of the HERG screening market is being propelled by the escalated numbers of patients diagnosed with heart disorders.

Explore Comprehensive Insights Into The Global HERG Screening Market With A Free Sample Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=14392&type=smp

What Companies Are At the Forefront of Innovation in the HERG Screening Market?

Major companies operating in the HERG screening market are:

• Eurofins-Cerep SA._x000D_

• Aviva Biosciences Inc._x000D_

• AstraZeneca Public Limited Company_x000D_

• Merck KGaA_x000D_

• Charles River Laboratories Inc._x000D_

How Are Emerging Trends in Consumer Behavior Affecting the HERG Screening Market?

Leading firms in the HERG screening market are focusing on the integration of innovative advanced solutions like GLP-certified HERG screening services to boost cardiac safety evaluations during the drug development process. This service entails the good laboratory practice-certified screening of the human ether-à-go-go related gene (hERG) through the traditional whole-cell patch-clamp method. This method ensures the screening aligns with regulatory protocols such as ICH S7A and ICH S7B which are crucial for safety pharmacology studies during the drug development stage. An illustration of this is when Metrion Biosciences Ltd., a pharmaceutical company based in the UK, introduced its good laboratory practice (GLP)-certified hERG screening service in August 2023. The aim of this service is to amplify Metrion’s assistance for the development of small molecule therapeutics and supplement the company’s existing cardiac safety services. Furthermore, this service employs the traditional whole-cell patch-clamp method to determine potential cardiac risks before initiating Phase 1 human clinical trials, offers regulatory advice for safety pharmacology studies in drug development, as well as providing clients with quality biology services for ion channel targets.

Secure Your Global HERG Screening Market Report Now for Fast and Efficient Delivery!

https://www.thebusinessresearchcompany.com/report/herg-screening-global-market-report

How Are Market Segments in the HERG Screening Industry Positioned for Long-Term Growth?

The HERG screening market covered in this report is segmented –

1) By Type: Gene KCNH2, Mutant KCNH2

2) By Ion Channel: Voltage-Gated, Ligand Gated

3) By Applications: Antiarrhythmic, Antipsychotic, Antibiotics, Other Applications

Subsegmeents:

1) By Gene KCNH2: Wild-Type KCNH2, Recombinant KCNH2

2) By Mutant KCNH2: Mutations: Missense Mutations, Nonsense Mutations, Frameshift Mutations

What Regions Are Propelling Growth in the HERG Screening Industry?

North America was the largest region in the HERG screening market in 2024. Asia-Pacific is expected to be the fastest growing region in the forecast period. The regions covered in the HERG screening market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Does the Definition of the HERG Screening Market Include?

Human Ether-à-go-go-related gene (HERG) screening refers to the process of assessing the potential cardiotoxicity of a drug or compound. HERG screening is an important component of preclinical safety assessment in drug discovery and development, ensuring the safety and efficacy of novel therapeutic agents.

Browse Through More Similar Reports By The Business Research Company:

Cellular Health Screening Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/cellular-health-screening-global-market-report

Crushing, Screening, And Mineral Processing Equipment Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/crushing-screening-and-mineral-processing-equipment-global-market-report

Blood Screening Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/blood-screening-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: